Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 18Glioma 11Neoplasms 6Brain Neoplasms 6Astrocytoma 6Neuroblastoma 4Sarcoma, Ewing 3Gliosarcoma 3Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Medulloblastoma 2Diffuse Intrinsic Pontine Glioma 2Wilms Tumor 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Refractory Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma, Follicular 1Hepatoblastoma 1Ganglioneuroblastoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2sargramostim 1montanide ISA 51 1incomplete Freund's adjuvant 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Phantoms, Imaging 1Methods 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Temozolomide × 30 days × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡